Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096443 · ClinicalTrials.gov registry record · Early Phase 1
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
A Early Phase 1 study of Multiple Sclerosis, sponsored by Griffin Hospital.
- Active
- Registry status
- Early Phase 1
- Development phase
- 9
- Enrollment target
- 1
- Study location
NCT04096443 is a Early Phase 1 study of Multiple Sclerosis that is active but no longer recruiting, run by Griffin Hospital. The registered enrollment target is 9 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04096443, a Early Phase 1 study of Multiple Sclerosis, is active but no longer recruiting, sponsored by Griffin Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 9 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.
Conditions Studied
Interventions
- BIOLOGICAL Fecal microbial transplant (FMT)
Study Locations (1)
Connecticut
- Griffin Hospital - Derby
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-10-28 |
| Est. Completion | 2024-12-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096443
The ClinicalTrials.gov registry entry for NCT04096443 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (98% lower). The listed sponsor is Griffin Hospital, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Fecal microbial transplant (FMT) is the first listed.
NCT04096443 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT04096443 about?
NCT04096443 is a clinical study titled "Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis". The goal of this pilot study is to determine whether fecal microbial transplant (FMT) has the potential to be an effective, safe and tolerable therapy for the treatment of multiple sclerosis (MS). The investigators plan to gather preliminary data in a small cohort of 10 to 15 adults with MS.
What is the current status of trial NCT04096443?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 9 participants. The study started on 2019-10-28. Estimated completion is 2024-12-30.
What conditions does trial NCT04096443 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT04096443?
The interventions under investigation include: Fecal microbial transplant (FMT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT04096443?
This trial is sponsored by Griffin Hospital, which has 22 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04096443 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Entire-body PET Scans for Multiple Sclerosis
RECRUITING · Early Phase 1
-
Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues
RECRUITING · Early Phase 1
-
Assessment of Synaptic Density in MS
RECRUITING · Early Phase 1
-
Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis
ACTIVE NOT RECRUITING · Early Phase 1
-
Novel Imaging Markers in SPMS
COMPLETED · Early Phase 1
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.